PT-141 Benefits: What the Research Has Actually Looked At

The medications Pepti prescribes:

Prices are all-in: medication, physician review, refill management and shipping, with no membership fee.

PT-141 is the development code for bremelanotide, a cyclic peptide of seven amino acids and a synthetic analogue of alpha-melanocyte-stimulating hormone. It activates melanocortin receptors, with MC1R and MC4R the two that matter at therapeutic doses; MC4R is the receptor implicated in sexual function. It came out of the Melanotan II research line in the 1990s, when men in those studies reported spontaneous erections and higher desire, and it was developed for that effect rather than for tanning. It is not a PDE5 inhibitor and does not act on blood flow, and it does not raise testosterone or oestrogen.

What was studied. RECONNECT was two identical 24-week, randomised, double-blind, placebo-controlled phase 3 trials published together in Obstetrics & Gynecology in 2019. They enrolled 1,267 premenopausal women with acquired, generalised hypoactive sexual desire disorder (HSDD) and randomised them to 1.75 mg bremelanotide or placebo, self-injected as needed.

What was reported. On the desire domain of the Female Sexual Function Index, scores improved by 0.30 and 0.42 points more than placebo in the two studies, both statistically significant.

The limits. Those are modest absolute differences. The FDA judged them meaningful enough to approve a product, approved on 21 June 2019 for this one population. The trials excluded women whose low desire was caused by a medication, a relationship problem, or another medical or psychiatric condition, and did not include postmenopausal women. They used a fixed 1.75 mg autoinjector, not a compounded multi-dose vial.

Strength: the strongest evidence of any benefit on this page, in a narrow population.

What was studied. The same two phase 3 trials measured distress using item 13 of the Female Sexual Distress Scale as a co-primary endpoint.

What was reported. Distress improved by 0.37 and 0.29 points more than placebo, both statistically significant. Both trials met both co-primary endpoints. A 52-week open-label extension, also in Obstetrics & Gynecology in 2019, followed 684 women who chose to continue; it reported no new safety signals, and only 272 completed the full year.

The limits. The same population limits apply. An open-label extension in people who chose to continue is not a controlled comparison, and the people who stayed are not a random sample of those who started.

Strength: randomised human data for the trial population.

What was studied. Before phase 3, a phase 2b dose-finding trial in Women's Health in 2016 randomised premenopausal women to placebo or 0.75, 1.25 or 1.75 mg bremelanotide, used as desired.

What was reported. In the 327 women analysed, the pooled 1.25 and 1.75 mg group reported more satisfying sexual events per month than placebo: +0.7 against +0.2.

The limits. A difference of about half an event a month, in one trial, in the same narrow population. This was a dose-finding study that set up the phase 3 programme rather than a test of it.

Strength: human, randomised, small absolute effect.

What was studied. A 2006 crossover study in the Journal of Sexual Medicine gave 18 premenopausal women with sexual arousal disorder a single 20 mg intranasal dose or placebo.

What was reported. More women reported moderate or high desire after bremelanotide than after placebo.

The limits. Eighteen women, one dose, and a nasal route that was later dropped. It is a historical data point, not evidence about a subcutaneous injection.

Strength: human, small, historical.

What was studied. The men's programme is where PT-141 started. Two 2004 papers in the International Journal of Impotence Research used double-blind, placebo-controlled designs in healthy men and in men with mild-to-moderate erectile dysfunction, including men who had responded inadequately to sildenafil.

What was reported. Statistically significant erectile responses to intranasal and subcutaneous PT-141, including responses without visual sexual stimulation, which is the signature of a drug acting in the brain rather than on blood flow.

The limits. These were small, clinic-based, early-phase studies that measured erectile response over hours, not sexual satisfaction over months. The men's programme did not lead to an approved product, and there is no phase 3 trial in men. Prescribing PT-141 to men is off-label use of an approved active ingredient.

Strength: human, randomised, early-phase only.

What was studied. A 2005 paper in Urology tested low-dose intranasal PT-141 together with sildenafil in men.

What was reported. The combination produced a larger erectile response than either alone, consistent with the two acting at different points in the pathway.

The limits. One small, early-phase study with an intranasal formulation. Whether a combination is appropriate depends on blood pressure and cardiovascular history, and it is reviewed at intake rather than assumed.

Strength: human, small, early-phase.

What the evidence is. This is a feature of how PT-141 was trialled and is used, not an outcome. The phase 3 trials used it as needed, and the approved label sets a ceiling of eight doses a month and no more than one in 24 hours. In the extension, most women used it two to three times a month. Pepti's typical PT-141 directions are 2 to 4 hours before sexual activity, no more than four doses a month.

Why people value it. There is no daily injection, and each dose stands on its own. No dependence, withdrawal or rebound is described in the trial programme.

The limits. As-needed use means each dose carries its own side effects, which arrive in the same window as the intended effect. The approved label states that the duration of effect has not been fully characterised.

What the evidence is. The approved label describes bremelanotide as a non-selective melanocortin receptor agonist with the potency order MC1R, MC4R, MC3R, MC5R, MC2R. A 2007 paper in the Journal of Sexual Medicine and a 2022 review in CNS Spectrums describe increased dopamine release in the medial preoptic area of the hypothalamus in female rats, a region associated with sexual motivation. The proposed model is that it increases the "wanting" side of sexual behaviour rather than the physical response.

Why it matters. It is a different route from PDE5 inhibitors, which act on blood vessels and need arousal to work, and from hormone treatments. That is why it has been studied in women as well as men.

The limits. The approved label itself states the mechanism by which it improves desire is unknown; the dopamine account is the leading explanation from animal work, not a settled one. A mechanism is not a benefit.

• Efficacy in men beyond early-phase erectile-response studies.
• Efficacy in postmenopausal women, who were not studied.
• That it enhances performance in people without a diagnosed problem; the approved label says it is not indicated for that.
• An effect on low desire caused by a medication, a relationship problem, or another medical or psychiatric condition, all trial exclusions.
• Anything about a compounded 2 mg/mL vial specifically, or the PT-141 + Oxytocin combination, which has never been studied as a combination. Oxytocin's controlled evidence for sexual function is small, intranasal and mostly null.
• Any timeline for how a given person will respond.

The benefits come with a well-described side-effect profile. In the phase 3 trials nausea was reported by 40% of women against 1.3% on placebo, followed by flushing (20%), injection-site reactions (13%), headache (11%) and vomiting (5%); 18% of treated women stopped because of an adverse reaction, against 2% on placebo. Each dose briefly raises blood pressure, peaking two to four hours after the dose, and focal darkening of the face, gums or breasts was reported in 1% of women dosing up to eight times a month. It should not be used with oral naltrexone, with uncontrolled hypertension or with heart disease. The full list, and when to call 911, is in PT-141 side effects.

Your physician sets your directions after reviewing your intake, and your directions are printed on the vial. The units, mL and mg detail is in PT-141 dosage. Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

The active ingredient, bremelanotide, is the basis of an FDA-approved drug, which is why compounded PT-141 does not depend on the FDA's 503A bulks list. The compounded vial is a different formulation and is not FDA approved; compounded medications are not FDA approved. Bremelanotide is not named on the 2026 WADA Prohibited List. See are peptides FDA approved.

PT-141 cannot be bought legitimately without a prescription. Sites selling it "for research use only" are not accountable for what is in the vial: identity, purity, sterility and concentration are untested. The prescription route:

1. Complete a free online intake covering your history, medications and what you want help with.
2. A physician licensed in your state reviews it, usually within 24 hours.
3. If it is appropriate, a PCAB-accredited, FDA-registered US 503A compounding pharmacy prepares it to that prescription. Lot test results are published at /quality/lab-results.
4. It ships refrigerated with your directions printed on the vial.
5. Your physician stays reachable for questions and dose changes.

Pepti prescribes PT-141 in every state except Oklahoma, plus DC Step by step: how to get PT-141 prescribed online. Comparisons: kisspeptin vs PT-141, PT-141 vs Melanotan II, and the wider picture in peptides for libido and peptides for women.